Furthermore, do the dysfunctional mechanism(s) proposed for RyR2 in HF share any similarities to those for CPVT, which might offer insights into novel treatments for the latter? The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.